SCHEMBL19008281

SCHEMBL19008281

Nc1nc(=O)n(C2OC(CO)C(O)C2O)cc1-c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
MTOR P42345 2/20 0.60
THRB P10828 1/20 0.60
MDM2 Q00987 1/20 0.60
NCOA1 Q15788 1/20 0.60
NCOA3 Q9Y6Q9 1/20 0.60
ALDH1A1 P00352 2/20 0.57
THPO P40225 2/20 0.57
GMNN O75496 1/20 0.57
TP53 P04637 1/20 0.57
NFKB1 P19838 1/20 0.57
DNMT1 P26358 1/20 0.57
HTT P42858 1/20 0.57
RAB9A P51151 1/20 0.57
BLM P54132 1/20 0.57
HBB P68871 1/20 0.57
PMP22 Q01453 1/20 0.57
MAPT P10636 1/20 0.51
CDA P32320 1/20 0.51
ADK P55263 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16805381 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL18871284 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16805408 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16781784 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16781785 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL2587140 1.00 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL2587789 0.90 LMNA (0.48) LMNAMTORTHRBMDM2NCOA1
SCHEMBL10888591 0.90 CD99 (0.48) LMNAMTORTHRBMDM2NCOA1
SCHEMBL10888582 0.90 CD99 (0.48) LMNAMTORTHRBMDM2NCOA1
SCHEMBL21283082 0.85 LMNA (0.44) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190255194-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX INC (US) 2019-08-22 US disclosed
US-10286086-B2 Alternative nucleic acid molecules and uses thereof MODERNATX, INC. (US) 2019-05-14 US disclosed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190255194-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 LMNA 571/4885MTOR 4711/4885THRB 3594/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 LMNA 571/4885MTOR 4711/4885THRB 3594/4885
US-10286086-B2 Alternative nucleic acid molecules and uses thereof NSUN2, RNGTT, NSUN3 LMNA 571/4885MTOR 4711/4885THRB 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.